Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer
- 1 December 1994
- journal article
- clinical trial
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 120 (12) , 754-757
- https://doi.org/10.1007/bf01194278
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian CancerJNCI Journal of the National Cancer Institute, 1994
- New cytostatic drugs in ovarian cancerAnnals of Oncology, 1993
- A phase I trial of taxol given by a 6-hour intravenous infusion.Journal of Clinical Oncology, 1991
- Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diamminedichloroplatinum(II).1991
- Treatment of testicular cancer: a new and improved model.Journal of Clinical Oncology, 1990
- High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: A phase II studyAnnals of Oncology, 1990
- Taxol: A Novel Investigational Antimicrotubule AgentJNCI Journal of the National Cancer Institute, 1990
- Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial NeoplasmsAnnals of Internal Medicine, 1989
- PHASE-I TRIAL OF TAXOL GIVEN AS A 3-HOUR INFUSION EVERY 21 DAYS1986
- Promotion of microtubule assembly in vitro by taxolNature, 1979